These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 35089113)

  • 21. Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.
    Salvarani C; Dolci G; Massari M; Merlo DF; Cavuto S; Savoldi L; Bruzzi P; Boni F; Braglia L; Turrà C; Ballerini PF; Sciascia R; Zammarchi L; Para O; Scotton PG; Inojosa WO; Ravagnani V; Salerno ND; Sainaghi PP; Brignone A; Codeluppi M; Teopompi E; Milesi M; Bertomoro P; Claudio N; Salio M; Falcone M; Cenderello G; Donghi L; Del Bono V; Colombelli PL; Angheben A; Passaro A; Secondo G; Pascale R; Piazza I; Facciolongo N; Costantini M;
    JAMA Intern Med; 2021 Jan; 181(1):24-31. PubMed ID: 33080005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tocilizumab for the Critically Ill With Severe COVID-19: A Community Hospital Case Series.
    McKenzie MG; Lee YM; Mathew J; Anderson M; Vo AT; Akinyele S; Narayanan M
    J Pharm Pract; 2022 Aug; 35(4):587-592. PubMed ID: 33736526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repurposed Tocilizumab in Patients with Severe COVID-19.
    Tian J; Zhang M; Jin M; Zhang F; Chu Q; Wang X; Chen C; Yue H; Zhang L; Du R; Zhao D; Zeng Z; Zhao Y; Liu K; Wang M; Hu K; Miao X; Zhang H
    J Immunol; 2021 Feb; 206(3):599-606. PubMed ID: 33298617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
    Antwi-Amoabeng D; Kanji Z; Ford B; Beutler BD; Riddle MS; Siddiqui F
    J Med Virol; 2020 Nov; 92(11):2516-2522. PubMed ID: 32436994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early clinical outcomes with tocilizumab for severe COVID-19: a two-centre retrospective study.
    Smoke SM; Raja K; Hilden P; Daniel NM
    Int J Antimicrob Agents; 2021 Feb; 57(2):106265. PubMed ID: 33338559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of tocilizumab therapy in critically ill patients with severe acute respiratory syndrome coronavirus 2.
    Saffo Z; Guo W; Springer K; Maksimowicz-McKinnon K; Kak V; McKinnon JE; Bhargava P
    J Osteopath Med; 2021 Jul; 121(8):705-714. PubMed ID: 34237804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tocilizumab therapy for severely-ill COVID-19 pneumonia patients: a single-centre retrospective study.
    Iqtadar S; Khan A; Mumtaz SU; Pascual-Figal DA; Livingstone S; Abaidullah S
    J Physiol Pharmacol; 2022 Aug; 73(4):. PubMed ID: 36696245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early use of tocilizumab in patients with severe pneumonia secondary to severe acute respiratory syndrome coronavirus 2 infection and poor prognostic criteria: Impact on mortality rate and intensive care unit admission.
    Sánchez-Rovira P; Pérez-Chica G; Ortega-Granados AL; Aguilar-García J; Díaz-Beltrán L; Gálvez-Montosa F; García-Verdejo F; Luque-Caro N; Quero-Blanco C; Fernández-Navarro M; Rodríguez-Sánchez A; Ruiz-Bailén M; Yaguez-Mateos L; Marín-Pozo JF; Sierra-Torres MI; Lacárcel-Bautista C; Duro-Ruiz GJ; Duro-Fernández MÁ; García-Alegría J; Herrero-Rodríguez C
    Medicine (Baltimore); 2021 Jul; 100(29):e26533. PubMed ID: 34398008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. No evidence of tocilizumab treatment efficacy for severe to critical SARS-CoV2 infected patients: Results from a retrospective controlled multicenter study.
    Burlacu R; London J; Fleury A; Sené T; Diallo A; Meyssonnier V; Zeller V; Galland J; Huscenot T; Rubenstein E; Trouiller P; Amathieu R; Kutter J; Blondeel D; Lejour G; Mouly S; Lidove O; Wladimir M; Sène D
    Medicine (Baltimore); 2021 May; 100(21):e26023. PubMed ID: 34032722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Longitudinal correlation of biomarkers of cardiac injury, inflammation, and coagulation to outcome in hospitalized COVID-19 patients.
    Li C; Jiang J; Wang F; Zhou N; Veronese G; Moslehi JJ; Ammirati E; Wang DW
    J Mol Cell Cardiol; 2020 Oct; 147():74-87. PubMed ID: 32827510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial.
    Tom J; Bao M; Tsai L; Qamra A; Summers D; Carrasco-Triguero M; McBride J; Rosenberger CM; Lin CJF; Stubbings W; Blyth KG; Carratalà J; François B; Benfield T; Haslem D; Bonfanti P; van der Leest CH; Rohatgi N; Wiese L; Luyt CE; Kheradmand F; Rosas IO; Cai F
    Crit Care Med; 2022 Mar; 50(3):398-409. PubMed ID: 34612846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tocilizumab is associated with reduced delirium and coma in critically ill patients with COVID-19.
    Alkhateeb T; Stollings JL; Sohn I; Liu D; Fleenor LM; Ely EW; Lahiri S
    Sci Rep; 2024 May; 14(1):11738. PubMed ID: 38778074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of the effectiveness of tocilizumab on mortality and progression to mechanical ventilation or intensive care in patients with COVID-19 admitted to a tertiary hospital.
    Pinilla Rello A; Magallón Martínez A; Vicente Iturbe C; Escolano-Pueyo A; Herranz Bayo E; Aguilo Lafarga I
    Eur J Hosp Pharm; 2024 Apr; 31(3):212-219. PubMed ID: 36150845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The association of interleukin-6 value, interleukin inhibitors, and outcomes of patients with COVID-19 in New York City.
    Maeda T; Obata R; Rizk DO D; Kuno T
    J Med Virol; 2021 Jan; 93(1):463-471. PubMed ID: 32720702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tocilizumab for the treatment of severe coronavirus disease 2019.
    Alattar R; Ibrahim TBH; Shaar SH; Abdalla S; Shukri K; Daghfal JN; Khatib MY; Aboukamar M; Abukhattab M; Alsoub HA; Almaslamani MA; Omrani AS
    J Med Virol; 2020 Oct; 92(10):2042-2049. PubMed ID: 32369191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Higher levels of IL-6 early after tocilizumab distinguish survivors from nonsurvivors in COVID-19 pneumonia: A possible indication for deeper targeting of IL-6.
    Quartuccio L; Sonaglia A; Pecori D; Peghin M; Fabris M; Tascini C; De Vita S
    J Med Virol; 2020 Nov; 92(11):2852-2856. PubMed ID: 32515499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tocilizumab reduces COVID-19 mortality and pathology in a dose and timing-dependent fashion: a multi-centric study.
    Durán-Méndez A; Aguilar-Arroyo AD; Vivanco-Gómez E; Nieto-Ortega E; Pérez-Ortega D; Jiménez-Pérez C; Hernández-Skewes KY; Montiel-Bravo G; Roque-Reyes OJ; Romero-Lechuga F; Medina-Santos D; Oriana-Román P; Flores-Hernández JR; Méndez-Coca JD; Montaño-Olmos D; Farfán-Lazos KC; Tobón-Cubillos M; Viveros-Hernández A; Sevilla-Castillo F; Hernández-Romero ÁR; Ortega-Rodríguez S; Jardínez-Vera AC; Solís-González MA; de la Medina AR; Pérez-Maldonado LM; Lagunes-Lara E; Cova-Bonilla M; Peón AN
    Sci Rep; 2021 Oct; 11(1):19728. PubMed ID: 34611251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tocilizumab treatment in COVID-19: A single center experience.
    Luo P; Liu Y; Qiu L; Liu X; Liu D; Li J
    J Med Virol; 2020 Jul; 92(7):814-818. PubMed ID: 32253759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome.
    Pandolfi L; Fossali T; Frangipane V; Bozzini S; Morosini M; D'Amato M; Lettieri S; Urtis M; Di Toro A; Saracino L; Percivalle E; Tomaselli S; Cavagna L; Cova E; Mojoli F; Bergomi P; Ottolina D; Lilleri D; Corsico AG; Arbustini E; Colombo R; Meloni F
    BMC Pulm Med; 2020 Nov; 20(1):301. PubMed ID: 33198751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.